The bcr-ablfusion gene is the molecular counterpart of the Philadelphia chromosome (Ph') and is directly involved in the pathogenesis of Ph'+ leukemia. Inhibition of bcr-ab/ gene expression may have profound effects on the cell biology of Ph'+ cells, as recent experiments with antisense oligonucleotides have shown. In this study we have designed and synthesized a unique ribozyme that is directed against bcr-ab/ mRNA. The ribozyme cleaved bcr-ab/ mRNA in a cell-free in vitro system. A DNA-RNA hybrid ribozyme was then incorporated into a liposome vector and HRONIC MYELOGENOUS leukemia (CML) arises C from the malignant transformation of a pluripotential stem cell and represents about 15% to 20% of all leukemias. The Philadelphia chromosome (Ph'), which results from a reciprocal translocation between chromosomes 9 and 22, is detectable in over 95% of patients with CML. This translocation results in transposition of the cellular ab1 (c-abl) gene from its usual position on chromosome 9 to chromosome 2 2 . '~~ The breakpoint on chromosome 22 at band q l 1 occurs within a limited 5.8-kb DNA segment termed the breakpoint cluster region or b~r ,~ which resides on a gene composed of 140 kb and 23 exons, now designated the BCR Transposition of c-ab1 into the BCR gene results in the creation of an abnormal fusion gene termed bcr-ab/, that occurs by fusing either bcr exon 3 to ab/ exon 2 (splice l), or bcr exon 2 to ab/ exon 2 (splice 2). The mRNA transcript that results from the fusion gene is 8.5 kb (+lo9 bases depending on whether bcr exon 3 is included or not) and is translated into a p2 10 protein with augmented tyrosine kinase activity. This p2 lokr-*' protein and its corresponding mRNA are found in virtually all patients with CML, even those in whom the common t(9;22) translocation is replaced by a variant translocation not apparently involving chromosome 9 or in whom no gross cytogenetic evidence of the Ph' is present.6 The p2 10kr-ab' is also found in about 50% of patients with Ph'+ acute lymphoblastic leukemia (ALL). In the other 50% of such patients, a protein is The ribozyme decreased levels of detectable bcr-ablmRNA in these cells, inhibited expression of the bcr-ablgene product, p21**"', and inhibited cell growth. This anti-bcr-ab/ ribozyme may be a useful tool to study the cell biology of Ph'+ leukemia and may ultimately have therapeutic potential in treating patients with Ph' leukemias.
C from the malignant transformation of a pluripotential stem cell and represents about 15% to 20% of all leukemias. The Philadelphia chromosome (Ph'), which results from a reciprocal translocation between chromosomes 9 and 22, is detectable in over 95% of patients with CML. This translocation results in transposition of the cellular ab1 (c-abl) gene from its usual position on chromosome 9 to chromosome 2 2 . '~~ The breakpoint on chromosome 22 at band q l 1 occurs within a limited 5.8-kb DNA segment termed the breakpoint cluster region or b~r ,~ which resides on a gene composed of 140 kb and 23 exons, now designated the BCR Transposition of c-ab1 into the BCR gene results in the creation of an abnormal fusion gene termed bcr-ab/, that occurs by fusing either bcr exon 3 to ab/ exon 2 (splice l), or bcr exon 2 to ab/ exon 2 (splice 2). The mRNA transcript that results from the fusion gene is 8.5 kb (+lo9 bases depending on whether bcr exon 3 is included or not) and is translated into a p2 10 protein with augmented tyrosine kinase activity. This p2 lokr-*' protein and its corresponding mRNA are found in virtually all patients with CML, even those in whom the common t(9;22) translocation is replaced by a variant translocation not apparently involving chromosome 9 or in whom no gross cytogenetic evidence of the Ph' is present. 6 The p2 10kr-ab' is also found in about 50% of patients with Ph'+ acute lymphoblastic leukemia (ALL). In the other 50% of such patients, a protein is detected with a correspondingly smaller mRNA of 7 to 7.5 kb. In this fusion gene the first exon of the BCR gene is spliced to the second exon of abl. [7] [8] [9] The bcr-ablgene has been shown to transform hematopoietic cells in vitro, suggesting that it may actually have a causal role in the development of CML." As further evidence for the critical role of the p2 l Obcr-ab' or p l 90kr-ab' protein, several investigators have reported that expression of this protein in mice using viral vectors in bone marrow transplant or transgenic mouse models leads to the development of CML-or ALL-like disease in many of these animal~."-'~ Ribozymes are a class of RNA molecules that can cleave other RNA sequences enzymatically.L6-20 These molecules have two domains: (1) the catalytic "hammerhead" portion that cleaves the target by a mechanism dependent on divalent cations (in particular, magnesium); and (2) the flanking sequences that confer specificity of binding of the ribozyme to the region of the RNA molecule that contains the target sequence. Any sequence of nucleotides of G-U-N, where N = A, C, or U, can be targeted by a ribozyme. In fact, it is possible that any sequence of N-U-N may be a potential target, although some sequences may not be cleaved as efficiently as others. Ribozymes act like enzymes in that one molecule can bind to its RNA target, cleave it, then dissociate and bind to a second target, and so on.
Ribozymes have tremendous potential to specifically inhibit the expression of a variety of genes and represent a novel therapeutic approach to controlling viral infections and oncogenesis. Researchers have begun to apply this technology to inhibit expression of human immunodeficiency virus genes,2'.22 as well as c-fosz3 and H-ras oncogenes in vitro and in animal models.
This approach is similar in some ways to the use of antisense molecules to inhibit expression of viral genomes, growth factors, and oncogene^.^^^^ For example, Anfossi et have used c-myb antisense oligodeoxynucleotides (oligos) to inhibit the growth of human myeloid leukemia cell lines and to demonstrate differential sensitivity to such inhibitory effects between normal and leukemic hematopoietic ~e l l s .~~,~~ These investigators have also used antisense oligos directed against the bcr-ab1 oncogene to inhibit cell growth of freshly isolated leukemic blasts from CML patients. 37 The aim of this study was to use ribozyme technology to inhibit expression of this bcr-ab/ gene in Ph'+ leukemia cellsand to evaluate the effect of this inhibition on cell proliferation. Specific ribozymes were synthesized both as RNA and as hybrid DNA-RNA oligonucleotides (oligos). The catalytic activity of the ribozyme was then analyzed both in a cell-free system and after transfection into a Ph'+ cell line, EM-2, using liposome vectors. The effects of the anti-bcrab/ ribozyme on bcr-ab/ gene expression and on EM-2 cell proliferation were then evaluated.
MATERIALS AND METHODS
Synthesis of anti-bcr-ab1 ribozyme. A "hammerhead" r i b zyme to cleave bcr-ab1 mRNA splice I (Fig I) was synthesized in the City of Hope DNA Synthesis Core facility. Ribozyme cDNA was subcloned to a pBluescript vector (Stratagene, La Jolla, CA) which was used to generate RNA ribozyme using T7 RNA polymerase in vitro. To increase the stability of the ribozyme to ribonucleases, the ribonucleotides (RNA) in the flanking arms and in a portion of the loop structure were replaced with deoxyribonucleotides (DNA).38. '9 This chemically synthetic construct is referred to as DNA-RNA Preparation of target bcr-ab1 splice I mRNA substrate. The pJWP3 plasmid containing bcr-ab1 splice 1 cDNA was kindly provided by Dr Owen Witte (University of California at Los Angeles). This cDNA was incorporated into the pBLUESCRIPT-KS(+) vector (Stratagene, La Jolla, CA), subcloned. and transcribed to RNA using T7 RNA polymerase and "P-UTP as described by Lowary et al."
Cellfree assay of ribozyme cleavage of bcr-ab1 mRNA. The in vitro ribozyme cleavage reactions were performed as described previously?' In brief, the in vitro ribozyme cleavage reactions were performed in 20-pL volume containing 2 pmol P'2-labeled bcr-ab1 target RNA in 75 mmol/L Tris-HCI pH 7.5 and 1 mmol/L Na-EDTA. The mixture was heated to 72°C for 2 minutes followed by rapid cooling on ice. To initiate the reaction, MgCI, was added to IO mmol/L, and the mixture was incubated for either 3 hours or 12 hours at 37°C. The reaction was stopped by the addition of formamide-EDTA dye, and the resulting mixture was analysed by 7 mol/ L urea 8% polyacrylamide gel electrophoresis (PAGE).
Ribozyme transfection of EM-2 cells. The EM-2 cell line (gift from Dr Owen Witte) is maintained in RPMl with 10% fetal calf serum (FCS) in our laboratory. During transfection, the EM-2 cells were washed two times with Opti-MEM I reduced Serum Medium (GIBCO, Gaithersburg, MD) and incubated with the same medium in a cell concentration of 2 X IO' per well in duplicate in 48-well plates for I hour. Then 6 pg of either oligos or ribozymes with 20 pglmL Transfectam (Lipopolyamine; Promega, Madison, WI) were added to the wells and incubated for 4 hours at 37°C. At 4 hours additional oligos or ribozymes were added without Transfectam to increase their final concentration to 4 pmol/L; FCS, 65°C inactivated, was added to each well to yield a final concentration of 4% in Opti-MEM reduced serum medium. Three additional doses of 2 pmol/L ofoligos or ribozyme were then added at 24,36, and 72 hours. Uptake of 32P-labeled ribozyme with Transfectam at 2 hours was 26%, compared to 9% without it.
-bcr -ab1 substrate CellproliJerarion assays. EM-2 cell counts and viability (trypan blue exclusion) were determined daily until the fourth day. Four hours after the third addition of oligos or ribozyme to the cultures (ie, at 76 hours), EM-2 cells (2 X IO') were directly seeded into duplicate methylcellulose dishes in the absence of hematopoietic growth factors and incubated for IO days at 37"C, 5% CO,,.with 1 5 8 FCS. The plates were then scanned for total numbers of colonies.
RNA analysis. EM-2 cells exposed for 48 hours to oligos or ribozymes were extracted for total cellular RNA by using guanidium isothiocyanide denaturing solution (RNAzol; Cinna-Biotex, Houston, TX). Bcr-ab1 mRNA was analyzed by ribonuclease protection assay RPA I1 (Ambion, Austin, TX), then scanned densimetrically by AMBlS systems (San Diego, CA). The 32P-labeled bcr-ab1 RNA probe used in this assay was synthesized from the opposite orientation of pBLUESCR1PTk-="vector by T3 RNA polymerase.
Immunoprecipitation and protein kinase assay 0Jp2lobcl*~' prorein. EM-2 cells treated with either oligos or ribozymes for 72 hours were extracted for cellular proteins. The assays were performed as described!' Cell lysates were immunoprecipitated with anti-bcr monoclonal antibody (bcr-Ab2, Oncogene Science, Manhasset, NY). Immune complexes were collected on protein A sepharose beads (Pharmacia Fine Chemicals, Piscataway, NJ) and kinase reactions performed in the presence of 32P-labeled adenosine triphosphate for 20 minutes at 37°C. The sizes of the autophosphorylated bcr and bcr-ab1 proteins were determined by 7% sodium dodecyl sulfate-PAGE (SDS-PAGE) followed by autoradiography.
Sluristical methods. Student's t-test was used to determine the significance of differences in mean cell numbers in the cell growth experiments.
RESULTS
Cell-jiree cleavage of bcr-ab1 mRNA. As shown in Fig 2, the anti-bcr-ab1 ribozyme cleaved bcr-ab1 mRNA splice 1 in an Mg++-dependent reaction. There was a 69% decrease in the amount of substrate remaining at 12 hours compared with a 25% decrease after 3 hours of incubation. The two cleavage products labeled as PI and P2 are the correct sizes predicted from the location of the cleavage site for the ribozyme, as shown in Fig 1. There is some degradation of the ribozyme after I2 hours in the presence of Mg++.
Both the RNA and DNA-RNA hybrid ribozymes were incubated for 1 hour at 37°C with RNase at varying concentrations to assess the relative stability of the hybrid ribozyme. The RNA r i b zyme was completely destroyed by RNase at 1 pg/mL. In contrast, approximately 50% and 10% of the hybrid ribozyme remained intact at RNase concentrations of I pg/mL and 5 pg/mL, respectively (data not shown). Figure 3 shows the results of a ribonuclease protection assay using a 32P-labeled bcr-ab1 RNA probe to detect bcr-ah1 mRNA extracted from EM-2 cells that had been incubated with the hybrid ribozyme or with various control oligos. Quantitative densimetric scanning of the autoradiogram showed a 49% decrease in detectable bcr-ab1 mRNA from EM-2 cells
Resistance of ribozyme to RNase.
Ribozyme effect on bcr-ab1 mRNA expression. For Ribozyme eflecf on EM-2 cell growth. The effect of anti-bcr-ab1 ribozyme on EM-2 cell growth was assessed both in liquid cultures and in methylcellulose colony formation assays. Figure 5 shows that in three similar experiments performed, the DH-Ribo inhibited EM-2 cell growth by 84%; the antisense oligo inhibited growth by 7 1%. These inhibitory effects were statistically significant by t-test both As an additional control, DH-Ribo, bcr-ab1 sense, and antisense oligos were added to Jurkat cells, a Phl-lymphoid cell line, and there was no effect on cell growth by any of these oligos (data not shown). The close proximity of the GUU nucleotide sequence to the bcr-ab1 mRNA fusion site suggested that a specifically designed ribozyme could be used to cleave the abnormal mRNA sequence. We have shown in this study that a ribozyme designed against the bcr-ab1 mRNA splice 1 can cleave this substrate in a cell-free system. More importantly, after transfection into a Ph'+ cell line, the ribozyme inhibits expression of both bcr-ab1 mRNA and the p2 10hr~ab'protein product and can inhibit growth of these cells in suspension and in methylcellulose cultures.
BCR PROTEINS
Ribozymes have been shown to have tremendous potenFor personal use only. on September 24, 2017. by guest www.bloodjournal.org From tial to inhibit the expression of a variety of genes and, thus, may represent a novel therapeutic approach to controlling viral infections and o n c~g e n e s i s .~' -~~ This approach is similar to the use of antisense oligos to inhibit expression of viral genomes, growth factors, and oncogenes.32 For example, Szczylik et ai3' have used antisense oligos directed against the bcr-ab1 oncogene to inhibit cell growth of freshly isolated leukemic blasts from CML patients. Ribozymes appear to act both as antisense oligos and as catalytic enzymes that cleave their substrate. A single ribozyme molecule can inactivate its target mRNA sequence by cleaving it, then dissociate from the two products, bind to a new target molecule, inactivate it, and so on. It should be noted that antisense RNA probes may also rehybridize with new substrate molecules and, thus, recycle. It was not our intention in this study to compare the inhibitory activity of anti-bcr-ab1 ribozymes directly with that of antisense oligos. It is difficult to control the intracellular concentrations of ribozyme and antisense molecules using our transfection method. Such a comparison may be more valid in a transduction model using a viral vector that allows for stable, long-term expression of these molecules.
We have used a liposome vector to transfect target cells with a ribozyme directed against bcr-ab1 mRNA. This approach is relatively inefficient and the expression of the ribozyme is short-lived. Recently, we have successfully cloned the anti-bcr-ab1 ribozyme gene into an adeno-associated viral (AAV) vector to achieve long-term, constitutive expression of the gene encoding the ribozyme in transduced target
In such a system we will be able to more accurately assess the efficacy of the ribozyme in blocking bcr-ab1 gene expression in cell lines and in freshly isolated leukemic cells. We will also be able to compare directly the relative efficiencies of anti-bcr-ab1 ribozyme and antisense molecules by transducing target cells with AAV constructs that contain and stably express either the ribozyme or antisense gene.
Our data showing that a ribozyme designed specifically against bcr-ab1 mRNA can inhibit expression of this gene and cell growth of a Ph'+ cell line further support the pathogenic role of the bcr-ab1 gene in Ph'+ leukemogenesis. In addition, anti-bcr-ab1 ribozymes may have therapeutic potential in the treatment of patients with Ph'+ leukemia using genetically modified marrow, leading to specific inhibition of leukemic cell proliferation without affecting normal hematopoietic precursors.
